Skip to content

Trevi Therapeutics, Inc. TRVI Net investment gains (losses)

Net investment gains (losses) at other companies

Repligen logo
RepligenRGEN
$0
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$21K+333%
National Bank Holdings logo
National Bank HoldingsNBHC
$246K
Grand Canyon Education logo
Grand Canyon EducationLOPE
-$100K+20.0%
Comstock Resources logo
Comstock ResourcesCRK
$2.4M+101%
Golub Capital logo
Golub CapitalGBDC
-$1.45M+91.4%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s net investment gains (losses).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s net investment gains (losses)?
Trevi Therapeutics, Inc. (TRVI) reported net investment gains (losses) of $0 in Q1 2026.
What does net investment gains (losses) mean?
Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.